HAL Allergy at a glance

Improving the quality of life with innovative causal allergy treatments for more than 60 years

HAL Allergy is one of the European top players in the field of allergy immunotherapy and has an internationally leading role in the production of modified allergen extracts for both, therapeutic and diagnostic purposes. We focus on the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases.

Since its foundation 1959, HAL Allergy grew to a well-established player in the AIT market with a highly competitive portfolio offering subcutaneous (SCIT) and sublingual (SLIT) products for pollen, house dust mites and insect venoms. Our GMP certified and state-of-the-art production facility is located in the Bio Science Park in Leiden, The Netherlands.

Developing a future-oriented product portfolio

With increasing prevalence of allergic diseases and rising numbers of resulting life-threatening emergency situations, HAL Allergy develops new therapeutics to increase quality of life for allergic patients and to serve our professional customers. Our development program encloses clinical trials for respiratory allergies (Ragweed, Mites) and food allergies (Peanut) to cover unmet medical need.

The partner for allergy experts

HAL Allergy focuses on the core group of allergy experts from the specialties of Ear Nose and Throat, Dermatology and Pulmonology. All of our activities are targeting to provide the best possible medical products and scientific output in order to increase quality of life for allergic patients and to serve our professional customers.

We work intensively in collaboration with our sales organizations, distributors and internationally acclaimed research institutes to identify the best possible combination of knowledge and experience.

HAL Allergy is a subsidiary of the family owned Droege Group

Droege Group (founded in 1988) is an independent advisory and investment company under full family ownership. The company acts as a specialist for tailor-made transformation programs aiming to enhance corporate value. Droege Group combines its corporate family-run structure and capital strength into a family-equity business model. The group carries out direct investments with its own equity in corporate spin-offs and medium-sized companies in ‘special situations’. With the guiding principle ‘execution – following the rules of art’, the group is a pioneer in execution-oriented corporate development.

Droege Group follows a focused investment strategy based on current megatrends (knowledge, connectivity, prevention, demography, specialization, future work, shopping 4.0). Enthusiasm for quality, innovation and speed determines the company’s actions. In recent years Droege Group has successfully positioned itself in domestic and international markets and operates in 30 countries.
More information: www.droege-group.com

Read more about HAL Allergy